Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
抑鬱症的微劑量：迷幻生物技術公司簽署了6,650萬美元的非約束性協議，以超越新型迷幻藥候選藥物的許可
Psychedelics biotech firm, Enveric Biosciences (NASDAQ:ENVB) has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, British Columbia-based biopharma company MindBio Therapeutics Corp CSE: MBIO, which is pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines.
迷幻藥生物技術公司Enveric Biosciences（納斯達克股票代碼：ENVB）簽署了一份不具約束力的條款表，向總部位於不列顛哥倫比亞省溫哥華的生物製藥公司MindBio Therapeutics Corp發放一類新型迷幻藥物（NPP）的許可證CSE：MBIO，它開創了使用微劑量迷幻藥物治療精神疾病的新療法。
The news comes on the heels of Enveric entering into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers.
該消息是在Enveric與一家未公開的生物技術公司（被許可人）簽訂不具約束力的條款表之後發佈的，該條款旨在獲得兩種旨在治療乳腺癌和其他癌症的專利方法的獨家許可。
Enveric's NPP molecules are designed to be metabolized specifically to release therapeutic levels...
Enveric的NPP分子經...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。